skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: Nome da Publicação: British Journal Of Cancer remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Mortality of patients with solid and haematological cancers presenting with symptoms of COVID-19 with vs without detectable SARS-COV-2: a French nationwide prospective cohort study
Mortality of patients with solid and haematological cancers presenting with symptoms of COVID-19 with vs without detectable SARS-COV-2: a French nationwide prospective cohort study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Mortality of patients with solid and haematological cancers presenting with symptoms of COVID-19 with vs without detectable SARS-COV-2: a French nationwide prospective cohort study

Assaad, Souad ; Zrounba, Philippe ; Cropet, Claire ; Blay, Jean-Yves

British journal of cancer, 2021-08, Vol.125 (5), p.658-671 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
2
Reply to the letter from Blay et al: Pretreatment serum CRP and response to interleukin 2
Reply to the letter from Blay et al: Pretreatment serum CRP and response to interleukin 2
Material Type:
Artigo 		Adicionar ao Meu Espaço

Reply to the letter from Blay et al: Pretreatment serum CRP and response to interleukin 2

Heys, Steven D ; Broom, John ; Eremin, Oleg

British journal of cancer, 1994-01, Vol.69 (1), p.201-201 [Periódico revisado por pares]

Nature Publishing Group

Texto completo disponível

Citações Citado por
3
Reply to the letter from Blay
Reply to the letter from Blay
Material Type:
Artigo 		Adicionar ao Meu Espaço

Reply to the letter from Blay

British journal of cancer, 1994-01, Vol.69 (1), p.201-201 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
4
Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study

Gelderblom, H. ; Jones, R.L. ; George, S. ; Morales, C.V. ; Benson, C. ; Blay, J.Y. ; Renouf, D.J. ; Doi, T. ; Cesne, A. le ; Leahy, M. ; Hertle, S. ; Aimone, P. ; Brandt, U. ; Schooffski, P.

British Journal of Cancer, 2020-03, Vol.122 (8), p.1158-1165

NATURE PUBLISHING GROUP

Texto completo disponível

Citações Citado por
5
Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma
Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma

RAVAUD, A ; NEGRIER, S ; CANY, L ; MERROUCHE, Y ; LE GUILLOU, M ; BLAY, J. Y ; CLAVEL, M ; GASTON, R ; OSKAM, R ; PHILIP, T

British journal of cancer, 1994-06, Vol.69 (6), p.1111-1114 [Periódico revisado por pares]

Basingstoke: Nature Publishing Group

Texto completo disponível

Citações Citado por
6
Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes
Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes
Material Type:
Artigo 		Adicionar ao Meu Espaço

Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes

Ménétrier-Caux, C ; Bain, C ; Favrot, M C ; Duc, A ; Blay, J Y

British journal of cancer, 1999-01, Vol.79 (1), p.119-130 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
7
Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study
Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study

Blay, Jean-Yves ; Schöffski, Patrick ; Bauer, Sebastian ; Krarup-Hansen, Anders ; Benson, Charlotte ; D'Adamo, David R ; Jia, Yan ; Maki, Robert G

British journal of cancer, 2019-05, Vol.120 (11), p.1026-1032 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
8
Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
Material Type:
Artigo 		Adicionar ao Meu Espaço

Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients

BACHELOT, T ; RAY-COQUARD, I ; MENETRIER-CAUX, C ; RASTKHA, M ; DUC, A ; BLAY, J-Y

British journal of cancer, 2003-06, Vol.88 (11), p.1721-1726 [Periódico revisado por pares]

Basingstoke: Nature Publishing Group

Texto completo disponível

Citações Citado por
9
Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials
Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials
Material Type:
Artigo 		Adicionar ao Meu Espaço

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials

CESNE, A. L ; JUDSON, I ; BLAY, J.-Y ; MAKI, R ; GROSSO, F ; SCHUETZE, S ; MEHREN, M. V ; CHAWLA, S. P ; DEMETRI, G. D ; NIETO, A ; TANOVIC, A

British journal of cancer, 2013-10, Vol.109 (7), p.1717-1724 [Periódico revisado por pares]

Basingstoke: Nature Publishing Group

Texto completo disponível

Citações Citado por
10
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study
Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study

Duffaud, Florence ; Blay, Jean-Yves ; Le Cesne, Axel ; Chevreau, Christine ; Boudou-Rouquette, Pascaline ; Kalbacher, Elsa ; Penel, Nicolas ; Perrin, Christophe ; Laurence, Valérie ; Bompas, Emmanuelle ; Saada-Bouzid, Esma ; Delcambre, Corinne ; Bertucci, François ; Cancel, Mathilde ; Schiffler, Camille ; Monard, Laure ; Bouvier, Corinne ; Vidal, Vincent ; Gaspar, Nathalie ; Chabaud, Sylvie

British journal of cancer, 2023-12, Vol.129 (12), p.1940-1948 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (257)

Data de Publicação 

De até
Refinar
  1. Antes de1996  (29)
  2. 1996Até2002  (47)
  3. 2003Até2009  (56)
  4. 2010Até2017  (92)
  5. Após 2017  (35)
  6. Mais opções open sub menu

Idioma 

  1. Japonês  (31)
  2. Russo  (1)
  3. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.